Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies.
Animals, Antibodies-Monoclonal, Genotype, Histocompatibility-Antigens-Class-I, Immunoglobulin-G, Mice-Inbred-C57BL, Mice-Transgenic, Models-Animal, Receptors-Fc, Transgenes
see Reprint Collection (a pdf is available).
Methods Mol Biol 2010; 602:93-104.
Therapeutic monoclonal antibodies are widely recognized to be a most promising means to treat an increasing number of human diseases, including cancers and autoimmunity. To a large extent, the efficacy of monoclonal antibody treatment is because IgG antibodies have greatly extended persistence in vivo. However, conventional rodent models do not mirror human antibody pharmacokinetics. The key molecule responsible for the extended persistence antibodies is the major histocompatibility complex class I family Fc receptor, FcRn. We describe human FcRn transgenic mouse models and how they can be exploited productively for the preclinical pharmacokinetic evaluation of therapeutic antibodies.
Roopenian, D C.; Christianson, G J.; and Sproule, T J., "Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies." (2010). Faculty Research 2010. 25.
Please contact the Joan Staats Library for information regarding this document.